• Something wrong with this record ?

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

R. Lakomy, A. Poprach, Z. Bortlicek, B. Melichar, R. Chloupkova, R. Vyzula, M. Zemanova, K. Kopeckova, M. Svoboda, O. Slaby, I. Kiss, H. Studentova, J. Juracek, O. Fiala, J. Kopecky, J. Finek, L. Dusek, K. Hejduk, T. Buchler,

. 2017 ; 17 (1) : 880. [pub] 20171221

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18033439

Grant support
NV15-34678A MZ0 CEP Register

BACKGROUND: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. RESULTS: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. CONCLUSIONS: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033439
003      
CZ-PrNML
005      
20201116155208.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-017-3901-5 $2 doi
035    __
$a (PubMed)29268716
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
245    10
$a Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry / $c R. Lakomy, A. Poprach, Z. Bortlicek, B. Melichar, R. Chloupkova, R. Vyzula, M. Zemanova, K. Kopeckova, M. Svoboda, O. Slaby, I. Kiss, H. Studentova, J. Juracek, O. Fiala, J. Kopecky, J. Finek, L. Dusek, K. Hejduk, T. Buchler,
520    9_
$a BACKGROUND: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). METHODS: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. RESULTS: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. CONCLUSIONS: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a papilární karcinom $x farmakoterapie $x sekundární $7 D002291
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $x sekundární $7 D007680
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a cílená molekulární terapie $7 D058990
650    _2
$a prognóza $7 D011379
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    12
$a záchranná terapie $7 D016879
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Chloupkova, Renata $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 499/2, 128 08, Prague, Czech Republic.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Juracek, Jaroslav $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology, Charles University and University Hospital, Svobody 80, 304 60, Pilsen, Czech Republic.
700    1_
$a Kopecky, Jindrich $u Department of Oncology, Hradec Králové University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology, Charles University and University Hospital, Svobody 80, 304 60, Pilsen, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Hejduk, Karel $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0227632
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59, Prague, Czech Republic. tomas.buchler@ftn.cz.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 17, č. 1 (2017), s. 880
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29268716 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20201116155206 $b ABA008
999    __
$a ok $b bmc $g 1340153 $s 1030433
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 17 $c 1 $d 880 $e 20171221 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options